A 48-year-old woman presented with abdominal pain, and her initial investigations, which included an abdominal ultrasound and a pelvic MRI examination, revealed a dominant soft tissue mass abutting her left iliac bone, extensive pelvic adenopathy, and multiple osseous metastases. The findings were concerning for chondrosarcoma; however, biopsy results were consistent with mucinous carcinoma of unknown origin. A staging 18F-FDG PET/CT revealed a mildly FDG-avid soft tissue mass with scattered calcifications extending to the dome of the urinary bladder, highly suggestive of a primary tumor. Cystoscopy with tissue sampling of this mass demonstrated a primary mucinous adenocarcinoma of the urachus.
Asian Pac J Cancer Prev, 15 (18), 7719-7724 IntroductionEsophageal cancer is the ninth malignant tumor in death in the world. There is an average of 150, 000 people died of esophageal cancer every year and ranked forth in China. The 5-year survival rate is less than 10% for patients suffering from esophageal cancer, and showed poor prognosis. The reason may be due to that the majority of patients have been diagnosed as advanced when perceived, and full-thickness esophageal wall has been involved or lymph node metastasis and distant metastasis has occurred. Lymph node metastasis and metastatic numbers are believed as dependent negative AbstractBackground: Lymph node metastasis is believed to be a dependent negative prognostic factor of esophageal cancer. To explore detection methods with high sensitivity and accuracy for metastases to regional and distant lymph nodes in the clinic is of great significance. This study focused on clinical application of FDG PET/CT and contrast-enhanced multiple-slice helical computed tomography (MSCT) in lymph node staging of esophageal cancer. Materials and Methods: One hundred and fifteen cases were examined with enhanced 64-slice-MSCT scan, and FDG PET/CT imaging was conducted for neck, chest and upper abdomen within one week. The primary lesion, location and numbers of metastatic lymph nodes were observed. Surgery was performed within one week after FDG PET/CT detection. All resected lesions were confirmed histopathologically as the gold standard. Comparative analysis of the sensitivity, specificity, and accuracy based on FDG PET/CT and MSCT was conducted. Results: There were 946 lymph node groups resected during surgery from 115 patients, and 221 were confirmed to have metastasis pathologically. The sensitivity, specificity, accuracy of FDG PET/CT in detecting lymph node metastasis were 74.7%, 97.2% and 92.0%, while with MSCT they were 64.7%, 96.4%, and 89.0%, respectively. A significance difference was observed in sensitivity (p=0.030), but not the others (p>0.05). The accuracy of FDG PET/CT in detecting regional lymph node with or without metastasis were 91.9%, as compared to 89.4% for MSCT, while FDG PET/CT and MSCT values for detecting distant lymph node with or without metastasis were 94.4% and 94.7%. No significant difference was observed for either regional or distant lymph node metastasis. Additionally, for detecting para-esophageal lymph nodes metastasis, the sensitivity of FDG PET/CT was 72%, compared with 54.7% for MSCT (p=0.029). Conclusions: FDG PET/CT is more sensitive than MSCT in detecting lymph node metastasis, especially for para-esophageal lymph nodes in esophageal cancer cases, although no significant difference was observed between FDG PET/CT and MSCT in detecting both regional and distant lymph node metastasis. However, enhanced MSCT was found to be of great value in distinguishing false negative metastatic lymph nodes from FDG PET/CT. The combination of FDG PET/CT with MSCT should improve the accuracy in lymph node metastasis staging of esophageal cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.